- Home
- KZIA vs XBIO Comparison
KZIA vs XBIO Comparison
Compare KZIA & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- XBIO
- Stock Information
- Founded
- KZIA 1994
- XBIO N/A
- Country
- KZIA Australia
- XBIO United States
- Employees
- KZIA N/A
- XBIO N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- XBIO Health Care
- Exchange
- KZIA Nasdaq
- XBIO Nasdaq
- Market Cap
- KZIA 6.0M
- XBIO 5.8M
- IPO Year
- KZIA 1999
- XBIO N/A
- Fundamental
- Price
- KZIA $0.77
- XBIO $2.59
- Analyst Decision
- KZIA Strong Buy
- XBIO Hold
- Analyst Count
- KZIA 2
- XBIO 1
- Target Price
- KZIA $11.50
- XBIO N/A
- AVG Volume (30 Days)
- KZIA 334.9K
- XBIO 6.9K
- Earning Date
- KZIA 04-11-2025
- XBIO 03-18-2025
- Dividend Yield
- KZIA N/A
- XBIO N/A
- EPS Growth
- KZIA N/A
- XBIO N/A
- EPS
- KZIA N/A
- XBIO N/A
- Revenue
- KZIA $1,655,324.00
- XBIO $2,500,284.00
- Revenue This Year
- KZIA N/A
- XBIO N/A
- Revenue Next Year
- KZIA N/A
- XBIO $27.78
- P/E Ratio
- KZIA N/A
- XBIO N/A
- Revenue Growth
- KZIA 248000.00
- XBIO N/A
- 52 Week Low
- KZIA $0.76
- XBIO $2.26
- 52 Week High
- KZIA $15.80
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- KZIA 35.51
- XBIO 24.42
- Support Level
- KZIA $0.76
- XBIO $2.26
- Resistance Level
- KZIA $1.05
- XBIO $3.43
- Average True Range (ATR)
- KZIA 0.08
- XBIO 0.23
- MACD
- KZIA -0.00
- XBIO -0.09
- Stochastic Oscillator
- KZIA 3.84
- XBIO 12.50
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.